Severe hypoglycemia is strongly associated with increased risks for a range of adverse clinical outcomes, including macrovascular and microvascular events and death, according to a new study.
Severe hypoglycemia is strongly associated with increased risks for a range of adverse clinical outcomes, including macrovascular and microvascular events and death, according to a study involving more than 11,000 patients with type 2 diabetes mellitus. Whether hypoglycemia is a causal factor or merely a marker of vulnerability to such events remains a mystery.
Australian researchers followed study participants for a median of 5 years. During that time, 231 had at least 1 severe hypoglycemic event; of these, 150 had been assigned to the intensive glucose control cohort, and 81 were in the standard glucose control group. Median times from the onset of severe hypoglycemia to the first major macrovascular event, the first major microvascular event, and death were 1.56 years, 0.99 years, and 1.05 years, respectively.
Compared with those without severe hypoglycemia, patients with the condition were almost 3 times as likely to suffer a major macrovascular event (hazard ratio [HR], 2.88; 95% confidence interval [CI], 2.01-4.12), almost twice as likely to suffer a major microvascular event (HR, 1.81; 95% CI, 1.19-2.74), almost 3 times as likely to die from a cardiovascular cause (HR, 2.68; 95% CI, 1.72-4.19), and almost 3 times as likely to die from any cause (HR, 2.69; 95% CI, 1.97-3.67; P<.001 for all comparisons). The researchers found similar associations for nonvascular conditions, including respiratory, digestive, and skin ailments.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More